9.2 C
New York
Wednesday, February 8, 2023

C4 Therapeutics Inc. (NASDAQ: CCCC): Is It A Buying Opportunity Again?

After Hours

After-hours and pre-market trading may carry slightly higher risks than regular market hours. As issuers often announce important financial information outside regular trading hours, extended-hours trading may result in wider spreads for a particular security. That is because extended-hours trading may result in lower liquidity and higher volatility. After-hours trades for C4 Therapeutics Inc. (CCCC) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.17, or -1.88%, to $8.85. The C4 Therapeutics Inc. has recorded 19,341 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that C4 Therapeutics Announces 2023 Strategic Priorities to Advance Portfolio of Targeted Protein Degradation Medicines.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Stocks Info

CCCC belongs to the Healthcare sector of the NASDAQ while operating in the Biotechnology industry. At the end of the last regular session, the stock closed at $9.02 and fluctuated between $9.10 as its day high and $7.98 as its day low. The current market capitalization of C4 Therapeutics Inc. is $427.82M. A total of 0.61 million shares were traded on the day, compared to an average of 451.93K shares.

Investors also take into account insider trades in predicting how the stock will perform in the future. During the recent three months, CCCC has seen 0 BUY and 0 SELL insider trades, representing the acquisition of 0 and the disposition of 0 shares. Over the last 12 months, there were 16 BUYs and 7 SELLs from insiders. Insiders purchased 48,929 shares during that period but sold 10,287.

In the most recent transaction, Hirsch Andrew bought 10,000 shares of CCCC for 8.40 per share on Apr 12. After the transaction, the President & CEO now owns 10,000 company shares.

While price targets are rarely accurate, they tend to exert some kind of influence from time to time and are often taken into account by investors. According to analysts who have offered 12-month price targets for CCCC in the last 3 months, the mean price target is $23.15 with high estimates of $84.00 and low estimates of $6.00. In terms of 52-week highs and lows, CCCC has a high of $31.13 and a low of $4.84.

As of this writing, CCCC has an earnings estimate of -$0.67 per share for the current quarter. EPS was calculated based on a consensus of 8 estimates, with a high estimate of -$0.4 per share and a lower estimate of -$0.8. The company reported an EPS of -$0.65 in the last quarter, which was -12.10% lower than expectations of -$0.58.

Balance Sheet Annually/Quarterly

An organization’s balance sheet depicts the assets and liabilities it has, as well as the amount of equity invested. Investors can measure a company’s prospects by calculating its financial ratios using this information.

Analysts Opinion

There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. Currently, 13 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CCCC is Hold with a score of 3.80. A total of 7 analysts rated the stock as Buy while 0 rated it as Overweight while 4 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 2 thought it should be Sold.

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles